The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Xinwei Huang
Project Title: Reproduce this article “Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests” and Conduct more in-depth research。
Date: [153]
Request ID: D2425
Aim 1: Reproduce this article “Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests” and Conduct more in-depth research。
Aim 2:
Aim 3:
Aim 4:
Investigator: Brian Gordon
Project Title: Evaluation of perivascular spaces and other markers of glymphatic function in sporadic Alzheimer’s Disease
Date: [153]
Request ID: D2426
Aim 1: Apply methods that are hypothesized to non-invasively measure glymphatic clearance. We primarily aim to look at enlarged PVS, but will also include low b-value DTI, DTI-ALPs, PET-tracer clearance, gGM-CSF-coupling, diffusion based IVIM, and ASL. This will give insight to which approaches best captur
Aim 2: Determine if there is a relationship between PVS, secondary imaging measures described in Aim 1, and unique biofluid measures of protein turnover. These will include SILK and Aβ40 measures.
Aim 3: Using a proteomic approach, evaluate if certain proteins are associated with enlarged PVS and glymphatic clearance.
Aim 4: Relate PVS, and our secondary imaging measures, to modifiable risk factors of AD. These will include sleep, obesity (BMI, height/weight), exercise, and cardiovascular health among other lifestyle factors. We also intend to look at sex differences in glymphatic clearance.
Investigator: Michael Ewers
Project Title: Analysis of proteomic signatures of MFG-E8 and medin amyloid in patients with Alzheimer’s disease
Date: [153]
Request ID: D2427
Aim 1: To test the association between MFG-E8 levels and neuroimaging markers of CAA
Aim 2: To test modulating factors of biofluid MFG-E8 levels in AD including APOE e4 genotype and vascular risk factors.
Aim 3: To determine the proteomic network and levels of medin associated with alterations in MFG-E8.
Aim 4:
Investigator: Peter Millar
Project Title: Comparing MRI and proteomic signatures of healthy aging
Date: [153]
Request ID: D2428
Aim 1: Test associations between model-predicted age estimates based on MRI (structural & resting-state functional connectivity), CSF proteomic measurements, and plasma organ age brain clocks.
Aim 2: Determine if proteins identified in the CSF proteomics aging model are associated with accelerated or decelerated aging in the MRI and plasma organ age brain clock aging models.
Aim 3: Determine if neuroimaging features identified in the MRI aging models are associated with accelerated or decelerated aging in the proteomic aging and plasma organ age brain clock aging models.
Aim 4: Compare MRI, CSF proteomic, and plasma organ age brain clock age estimates in detecting preclinical and symptomatic Alzheimer disease (AD).